PRESS RELEASE published on 09/13/2025 at 00:00, 7 months 26 days ago Onco-Innovations to Chair Colorectal Cancer Canada Precision Oncology Forum Driving the Future of Cancer Care Onco-Innovations to lead CRC Catalysts roundtable on data innovation and digital trust in oncology, advancing precision medicine. Enhanced by expert speakers, including Dr. Paul Arora Precision Medicine Digital Trust Onco-Innovations Data Innovation CRC Catalysts
BRIEF published on 09/05/2025 at 15:05, 8 months 3 days ago Onco-Innovations nomme le Dr John Mackey au conseil consultatif Essais Cliniques John Mackey Oncologie Onco-Innovations Inhibiteur De PNKP
BRIEF published on 09/05/2025 at 15:05, 8 months 3 days ago Onco-Innovations Appoints Dr. John Mackey to Advisory Board Clinical Trials Oncology John Mackey Onco-Innovations PNKP Inhibitor
PRESS RELEASE published on 09/05/2025 at 15:00, 8 months 3 days ago Onco-Innovations Appoints Dr. John Mackey to Scientific & Clinical Advisory Board Onco-Innovations appoints Dr. John Mackey, expert in oncology and clinical trials, to Scientific & Clinical Advisory Board, enhancing translational research capabilities for PNKP inhibitor program Clinical Trials Oncology Onco-Innovations PNKP Inhibitor Dr. John Mackey
BRIEF published on 08/15/2025 at 15:20, 8 months 24 days ago Onco-Innovations atteint un taux d'exercice de mandat élevé Financement Non Dilutif Confiance Des Actionnaires Mandats Stratégie De Capital Recherche Sur Le Cancer
BRIEF published on 08/15/2025 at 15:20, 8 months 24 days ago Onco-Innovations Achieves High Warrant Exercise Rate Warrants Non-dilutive Financing Cancer Research Shareholder Confidence Capital Strategy
PRESS RELEASE published on 08/15/2025 at 15:15, 8 months 24 days ago Onco-Innovations Announces 90% of $0.60 Warrants Have Been Exercised Onco-Innovations announces successful execution of key capital strategy with over 90% of outstanding warrants exercised at $0.60, reinforcing investor confidence and internal financing effectiveness Warrants Investor Confidence Capital Strategy Onco-Innovations Internal Financing
BRIEF published on 08/13/2025 at 23:05, 8 months 26 days ago Onco-Innovations clôture un placement privé de 400 000 $ Placement Privé Réglementation Des Valeurs Mobilières Actions Et Bons De Souscription Onco-Innovations Financement Et Développement
BRIEF published on 08/13/2025 at 23:05, 8 months 26 days ago Onco-Innovations Closes $400,000 Private Placement Private Placement Securities Regulation Shares And Warrants Onco-Innovations Funding And Development
PRESS RELEASE published on 08/13/2025 at 23:00, 8 months 26 days ago Onco-Innovations Announces Closing of Private Placement Onco-Innovations Limited announces the closing of a non-brokered private placement, raising $400,000 for general corporate purposes and cancer research. Statutory hold period applies. Not for distribution in the US Non-brokered Private Placement Cancer Research Statutory Hold Period Onco-Innovations Limited Not For Distribution
Published on 05/09/2026 at 01:30, 10 hours 1 minute ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 11 hours 31 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 20:38, 14 hours 53 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 16 hours 18 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 16 hours 29 minutes ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 16 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 16 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 16 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 16 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 16 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
